EUVIMEDOpdag EUVIMED
Open access

Human RNASET2 derivatives as potential anti-angiogenic agents: actin binding sequence identification and characterization

Liron Nesiel-Nuttman, Shani Doron, Betty Schwartz, Oded Shoseyov

Oncoscience · 2014

DOI: 10.18632/oncoscience.100 ↗

At a glance

Journal article in Oncoscience, 2014. Written by Liron Nesiel-Nuttman and 3 co-authors. Institution: The Robert H. Smith Institute of Plant Science and Genetics in Agriculture, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Heb…. Cited 8 times so far (Crossref); 38 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Human RNASET2 (hRNASET2) has been demonstrated to exert antiangiogenic and antitumorigenic effects independent of its ribonuclease capacity. We suggested that RNASET2 exerts its antiangiogenic and antitumorigenic activities via binding to actin and consequently inhibits cell motility. We focused herein on the identification of the actin binding site of hRNASET2 using defined sequences encountered within the whole hRNASET2 protein. For that purpose we designed 29 different hRNASET2-derived peptides. The 29 peptides were examined for their ability to bind immobilized actin. Two selected peptides-A103-Q159 consisting of 57 amino acids and peptide K108-K133 consisting of 26 amino acids were demonstrated to have the highest actin binding ability and concomitantly the most potent anti-angiogenic activity. Further analyses on the putative mechanisms associated with angiogenesis inhibition exerted by peptide K108-K133 involved its location during treatment within the HUVE cells. Peptide K108-K133 readily penetrates the cell membrane within 10 min of incubation. In addition, supplementation with angiogenin delays the entrance of peptide K108-K133 to the cell suggesting competition on the same cell internalization route. The peptide was demonstrated to co-localize with angiogenin, suggesting that both molecules bind analogous cellular epitopes, similar to our previously reported data for ACTIBIND and trT2-50.

Subjects

Author keywords

RNASET2actin-bindingantiangiogenesispeptidesribonuclease

Authors and institutions

  • The Robert H. Smith Institute of Plant Science and Genetics in Agriculture, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, ISRAEL.
  • School of Nutritional Sciences Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, ISRAEL.

Cite

APA

Nesiel-Nuttman, L., Doron, S., Schwartz, B., & Shoseyov, O. (2014). Human RNASET2 derivatives as potential anti-angiogenic agents: actin binding sequence identification and characterization. Oncoscience. https://doi.org/10.18632/oncoscience.100

Vancouver

Nesiel-Nuttman L, Doron S, Schwartz B, Shoseyov O. Human RNASET2 derivatives as potential anti-angiogenic agents: actin binding sequence identification and characterization. Oncoscience. 2014. doi:10.18632/oncoscience.100

BibTeX
@article{NesielNuttman2014,
  author = {Nesiel-Nuttman, Liron and Doron, Shani and Schwartz, Betty and Shoseyov, Oded},
  title = {Human RNASET2 derivatives as potential anti-angiogenic agents: actin binding sequence identification and characterization},
  journal = {Oncoscience},
  year = {2014},
  doi = {10.18632/oncoscience.100}
}
Start for free →